WO2009047800A3 - Oral controlled release composition of carvedilol - Google Patents
Oral controlled release composition of carvedilol Download PDFInfo
- Publication number
- WO2009047800A3 WO2009047800A3 PCT/IN2008/000652 IN2008000652W WO2009047800A3 WO 2009047800 A3 WO2009047800 A3 WO 2009047800A3 IN 2008000652 W IN2008000652 W IN 2008000652W WO 2009047800 A3 WO2009047800 A3 WO 2009047800A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carvedilol
- controlled release
- oral controlled
- pharmaceutically acceptable
- release composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An oral controlled release pharmaceutical composition comprising a carvedilol or a pharmaceutically acceptable salt(s) thereof. The oral controlled release pharmaceutical composition comprises a core comprising a therapeutically effective amount of carvedilol or a pharmaceutically acceptable salt(s) thereof and/or other pharmaceutically acceptable excipient thereof; and a functional coating comprising one or more pH dependent polymer(s), water soluble pore forming agent and/or other pharmaceutically acceptable excipient(s) thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1385/KOL/2007 | 2007-10-09 | ||
IN1385KO2007 | 2007-10-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2009047800A2 WO2009047800A2 (en) | 2009-04-16 |
WO2009047800A3 true WO2009047800A3 (en) | 2009-08-13 |
Family
ID=40275982
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IN2008/000652 WO2009047800A2 (en) | 2007-10-09 | 2008-10-08 | Oral controlled release composition of carvedilol |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2009047800A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110229564A1 (en) * | 2010-03-22 | 2011-09-22 | Amneal Pharmaceuticals, L.L.C. | Pharmaceutical Compositions Of Carvedilol Salts And Process For Preparation Thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040019096A1 (en) * | 2001-10-23 | 2004-01-29 | Vlassios Andronis | Novel formulations of carvedilol |
WO2004056336A2 (en) * | 2002-12-20 | 2004-07-08 | Ranbaxy Laboratories Limited | Controlled release, multiple unit drug delivery systems |
US20050175695A1 (en) * | 2003-11-25 | 2005-08-11 | Catherine Castan | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
WO2006044202A2 (en) * | 2004-10-19 | 2006-04-27 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid |
WO2007023325A2 (en) * | 2005-08-26 | 2007-03-01 | Egis Gyógyszergyár Nylvánosan Müködo Részvénytársaság | Controlled release pharmaceutical composition containing carvedilol |
WO2008070072A2 (en) * | 2006-12-01 | 2008-06-12 | Mutual Pharmaceutical Company, Inc. | Carvedilol forms, compositions, and methods of preparation thereof |
WO2008083130A2 (en) * | 2006-12-26 | 2008-07-10 | Dr. Reddy's Laboratories Limited | Amorphous and crystalline form a of carvedilol phosphate |
-
2008
- 2008-10-08 WO PCT/IN2008/000652 patent/WO2009047800A2/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040019096A1 (en) * | 2001-10-23 | 2004-01-29 | Vlassios Andronis | Novel formulations of carvedilol |
WO2004056336A2 (en) * | 2002-12-20 | 2004-07-08 | Ranbaxy Laboratories Limited | Controlled release, multiple unit drug delivery systems |
US20050175695A1 (en) * | 2003-11-25 | 2005-08-11 | Catherine Castan | Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
WO2006044202A2 (en) * | 2004-10-19 | 2006-04-27 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University | Enteric coated compositions that release active ingredient(s) in gastric fluid and intestinal fluid |
WO2007023325A2 (en) * | 2005-08-26 | 2007-03-01 | Egis Gyógyszergyár Nylvánosan Müködo Részvénytársaság | Controlled release pharmaceutical composition containing carvedilol |
WO2008070072A2 (en) * | 2006-12-01 | 2008-06-12 | Mutual Pharmaceutical Company, Inc. | Carvedilol forms, compositions, and methods of preparation thereof |
WO2008083130A2 (en) * | 2006-12-26 | 2008-07-10 | Dr. Reddy's Laboratories Limited | Amorphous and crystalline form a of carvedilol phosphate |
Also Published As
Publication number | Publication date |
---|---|
WO2009047800A2 (en) | 2009-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007054976A3 (en) | Lipid based controlled release pharmaceutical composition | |
WO2007133583A3 (en) | Zero-order modified release solid dosage forms | |
WO2009085990A3 (en) | Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof | |
WO2009055306A3 (en) | Coating designs for the tailored release of dual drugs from polymeric coatings | |
WO2010037854A3 (en) | Alcohol-resistant sustained-release oral pharmaceutical form based on microgranules | |
WO2007025005A3 (en) | Sustained release formulations of nalbuphine | |
WO2011084618A3 (en) | Compositions and methods for oral drug delivery | |
WO2007087431A3 (en) | Sublingual fentanyl spray | |
WO2006082523A3 (en) | Pharmaceutical sustained release composition of metformin | |
WO2010015567A3 (en) | Controlled release formulations using intelligent polymers | |
WO2008011335A3 (en) | Metal binding compounds, metal binding compositions, and their uses | |
WO2009047802A3 (en) | Novel colon targeted modified release bioadhesive formulation of 5-amino salicylic acid or its salts and metabolites thereof | |
WO2007109057A3 (en) | Solid dosage form containing a taste masked active agent | |
WO2007144169A3 (en) | Entacapone-derivatives | |
WO2009057138A3 (en) | Controlled release pharmaceutical compositions of tolterodine | |
WO2012022919A3 (en) | Nalbuphine-based formulations and uses thereof | |
WO2008084698A1 (en) | Tacrolimus sustained release pharmaceutical composition | |
NZ594311A (en) | Pharmaceutical composition comprising tamsulosin and solifenacin for oral administration | |
WO2006044077A3 (en) | Controlled release composition with semi-permeable membrane and poloxamer flux enhancer | |
WO2006008173A3 (en) | Pharmaceutical formulations for inhalation | |
WO2011037976A3 (en) | Pramipexole pharmaceutical formulations | |
WO2009149058A8 (en) | Modified release niacin formulations | |
WO2010046932A3 (en) | Extended release pharmaceutical composition of minocycline and process thereof | |
WO2007110753A3 (en) | Extended release dosage forms of metoprolol | |
WO2008035229A3 (en) | Compositions and methods for ph targeted drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08837487 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 08837487 Country of ref document: EP Kind code of ref document: A2 |